MARKHAM, ON, Dec. 6 /PRNewswire-FirstCall/ - AlphaRx AlphaRx, a leader in the development of Nanotechnology for Drug Delivery Platforms, announced a major product launch in China. Through AlphaRx International Holdings (AIH), its Hong Kong affiliate, AlphaRx will launch Indaflex(TM) in 2008. Already a successful topical arthritis relief product in Mexico, AIH is building a plant in China to meet the expected demand. AIH will also produce Dicloflex(TM), an eye-drop formula used to treat ocular inflammation and pain, as well as Vansolin(TM) and Zysolin(TM), used for serious infections such as lung inflammation and nosocomial pneumonia, for the rapidly growing Chinese market. Michael Lee, chairman of AlphaRx, said, “this is the beginning of a major push into the world’s biggest market. And with a permanent presence in Hong Kong through AIH, we are here to succeed over the short- and long-term.”
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietary site-specific nanoparticulate drug delivery systems to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method. The Company also discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.
CONTACT: Nucap Investor Relations, Web: http://www.thenucap.com; Anthony
Orlando, Managing Partner, E-mail: aorlando@thenucap.com, 629 Fifth Avenue,
Suite 300, Pelham, NY 10803, (914) 924-7437